HolderBook

BVF INC/IL

Reported holdings as of Q2 2026, from 31 quarterly filings.

This filer last reported in Q2 2026; the most recent quarter on file across all filers is Q3 2026. Firms that restructure stop filing under one CIK and start under another, so a successor entity may hold these positions now under a similar name.

CIK
1056807
Reported value
$3.9B
Positions
44
Top 10 weight
65.6%
Filed
2026-08-14
Days after quarter end
45

Holdings

Download these holdings as CSV

SecurityTickerValue SharesWeightWeight change Held Change
REVOLUTION MEDICINES INCRVMD$555.3M2,965,16014.20%+5.35pp26q+3.8%+$20.3M
KYMERA THERAPEUTICS INCKYMR$444.0M3,872,05211.35%-3.25pp24q-29.6%-$187.0M
XOMA ROYALTY CORPORATIONXOMA$322.7M7,593,3038.25%+5.66pp31q+193.1%+$212.6M
MOONLAKE IMMUNOTHERAPEUTICSMLTX$311.5M16,001,2847.97%-1.54pp17qHELD
GH RESEARCH PLCGHRS$232.5M8,650,1585.95%+2.07pp21qHELD
STRUCTURE THERAPEUTICS INCGPCR$180.7M3,366,8234.62%-0.69pp14q-2.7%-$5.0M
NEKTAR THERAPEUTICSNKTR$166.9M2,391,0754.27%-1.60pp4q-6.6%-$11.8M
MIRUM PHARMACEUTICALS INCMIRM$123.6M1,056,0273.16%-1.50pp12q-33.4%-$61.9M
XENCOR INCXNCR$114.9M7,133,7202.94%+0.20pp8qHELD
ALKERMES PLCALKS$112.9M2,154,7042.89%+0.63pp2q+7.7%+$8.1M
MONTE ROSA THERAPEUTICS INCGLUE$108.0M4,460,8862.76%+0.42pp7qHELD
CULLINAN THERAPEUTICS INCCGEM$104.7M5,750,6832.68%+0.07pp22qHELD
PALVELLA THERAPEUTICS INC NEPVLA$102.8M672,7892.63%-1.19pp7q-30.0%-$44.0M
ZYMEWORKS INCZYME$95.4M3,649,1422.44%-0.54pp15q-2.3%-$2.2M
KURA ONCOLOGY INCKURA$92.7M8,445,7692.37%+0.18pp31qHELD
DISC MEDICINE INCIRON$84.4M1,153,6122.16%-0.43pp3q-9.3%-$8.7M
STOKE THERAPEUTICS INCSTOK$83.4M2,547,5572.13%-0.51pp4qHELD
OLEMA PHARMACEUTICALS INCOLMA$66.3M5,295,8931.69%-0.82pp23qHELD
ANNEXON INCANNX$49.7M8,698,1731.27%-0.27pp11qHELD
CRESCENT BIOPHARMA INC.CBIO$49.5M2,748,7631.27%-0.34pp5qHELD
AC IMMUNE SAACIU$47.2M19,822,4361.21%-0.53pp31qHELD
TYRA BIOSCIENCES INCTYRA$47.1M1,476,1961.21%-1.21pp20q-25.3%-$16.0M
SUTRO BIOPHARMA INCSTRO$41.6M1,251,7881.06%+0.07pp2qHELD
IMMUNOCORE HLDGS PLCIMCR$41.1M1,294,4631.05%-0.19pp5qHELD
AVALO THERAPEUTICS INCAVTX$38.4M2,075,5450.98%+0.20pp8q+27.1%+$8.2M
4D MOLECULAR THERAPEUTICS INFDMT$38.3M2,879,2890.98%+0.13pp23qHELD
Q32 BIO INCQTTB$29.9M2,350,0000.77%-newNEW
ANTERIS TECHNOLOGIES GLOBALAVR$29.6M3,000,0000.76%+0.23pp2qHELD
FOGHORN THERAPEUTICS INCFHTX$28.5M5,842,0000.73%-0.16pp9qHELD
ABSCI CORPORATIONABSI$27.4M2,361,6740.70%-newNEW
ELEDON PHARMACEUTICALS INCELDN$24.8M6,293,2820.63%+0.02pp22qHELD
INVIVYD INCIVVD$24.6M28,165,0000.63%-0.18pp3q+44.3%+$7.5M
SAGIMET BIOSCIENCES INCSGMT$19.3M2,500,0000.49%-newNEW
ONKURE THERAPEUTICS INCOKUR$14.8M3,235,7780.38%+0.12pp2q+63.5%+$5.7M
IMMUNIC INCIMUX$11.8M765,2950.30%-newNEW
X4 PHARMACEUTICALS INCXFOR$10.4M2,233,7420.27%-0.03pp4qHELD
IMAGENEBIO INCIMA$6.5M1,110,0020.17%-0.01pp4qHELD
TSCAN THERAPEUTICS INCTCRX$5.5M5,564,2900.14%-0.04pp13qHELD
RESEARCH ALLIANCE CORP IIIRACC$5.3M500,0000.14%-newNEW
MOLECULAR PARTNERS AGMOLN$5.1M1,353,9680.13%-0.04pp20qHELD
TENAX THERAPEUTICS INCTENX$4.9M339,5490.13%-0.05pp8qHELD
ENTERA BIO LTDENTX$4.3M2,425,0000.11%-newNEW
INVENTIVA SAIVA$2.6M686,0400.07%-0.05pp22qHELD
ENGENE THERAPEUTICS INC$274.1K945,4020.01%-newNEW

By sector

Industry comes from the SIC code on each company's own SEC filings, which is self-reported and sometimes out of date. Derivative exposure is counted with the shares. Securities the SEC assigns no industry - funds, trusts, foreign issues - are shown as not classified rather than dropped.

Biotech & Pharma 90.8%Other sectors 0.8%Not classified 8.4%
 
SectorValueShare
Biotech & Pharma$3.6B90.8%
Other sectors$29.6M0.8%
Not classified$328.3M8.4%

What the disclosed book did

This is not the fund's return. A 13F shows long US equity positions only, so shorts, bonds, foreign listings, private holdings and cash are all invisible here. What this measures is the quarter's change in value of the positions this manager disclosed, had they been left untouched - the return a reader following the filing would have earned.

QuarterBookMarket DifferencePriced
Q2 2026+26.3%+14.8%+11.5%99%
Q1 2026+4.9%-4.6%+9.5%99%
Q4 2025+46.9%+2.4%+44.6%100%
Q3 2025-0.1%+7.8%-8.0%100%
Q2 2025+19.3%+10.5%+8.8%99%
Q1 2025-21.1%-4.6%-16.5%100%
Q4 2024-9.7%+2.1%-11.9%100%
Q3 2024+8.8%+5.4%+3.4%100%

Market is SPY over the same two quarter ends, priced the same way as everything else here - the median across every filer reporting it. It is a large-cap US proxy, so a manager holding small caps or biotech will beat or trail it for reasons that are not skill. Prices are quarter-end to quarter-end and say nothing about the path in between, or about trades opened and closed inside a quarter.

Quarter by quarter

QuarterValuePositions NewAddedTrimmed ExitedTop 10 Days to file
Q2 2026$3.9B44768465.6%45
Q1 2026$3.1B4141011462.2%45
Q4 2025$3.0B41278762.8%48
Q3 2025$2.5B46789558.6%45
Q2 2025$2.8B443561076.9%45
Q1 2025$2.5B512125473.5%45
Q4 2024$3.0B5351013770.1%45
Q3 2024$3.4B555691065.0%45
Q2 2024$3.6B60686861.0%45
Q1 2024$3.6B6234121162.3%45
Q4 2023$4.0B707107661.9%45
Q3 2023$3.7B69679463.7%45
Q2 2023$3.6B676821161.0%45
Q1 2023$2.7B7241861049.2%45
Q4 2022$2.4B7896171145.2%45
Q3 2022$2.4B8041116342.3%45
Q2 2022$2.1B7971911944.1%46
Q1 2022$2.5B816324845.6%46
Q4 2021$2.8B8311248346.5%45
Q3 2021$2.6B75101811548.1%46
Q2 2021$2.7B7091815654.6%47
Q1 2021$2.7B671214191352.3%47
Q4 2020$2.5B68141521854.0%43
Q3 2020$1.8B6291911445.8%44
Q2 2020$1.6B5781925848.0%45
Q1 2020$1.1B5751718557.4%45
Q4 2019$1.3B5761312860.3%45
Q3 2019$951.8M5991512650.6%45
Q2 2019$915.6M5692118650.4%45
Q1 2019$893.1M5341514649.9%45
Q4 2018$765.2M55000052.7%45

Rows marked UNVERIFIED ID, PLACEHOLDER ID, TICKER AS ID or NON-CUSIP ID carry an identifier that is not a valid CUSIP. They are shown because the filer reported that money, but treat the security named with caution - hover the chip for what is wrong with it, and see the methodology.

Held counts consecutive filings in which this manager reported the position, and can reach further back than the quarters listed above: the tabs begin at Q4 2018 because earlier coverage is too sparse to describe a market, but tenure is counted over every filing we hold, some reaching to 2007. A position sold and later rebought starts again from one.

Weight change is the shift in this position's share of the whole book, in percentage points. It is the more useful column: when money flows into or out of a broad fund, almost every holding is bought or sold at once, so added and trimmed largely track flows. A weight that rose while the book shrank is a decision. Both compare with the previous quarter this filer reported, not the previous calendar quarter.